SOUTH SAN FRANCISCO, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Mr. Tobin Schilke as Chief Financial Officer, effective July 5, 2016. Mr. Schilke will serve as Achaogen’s principal financial and accounting officer and will report to Kenneth Hillan, Chief Executive Officer.
“We are extremely pleased to have Toby joining the Achaogen team – he is a proven executive who has shaped and led successful teams,” said Kenneth Hillan, chief executive officer of Achaogen. “We look forward to leveraging Toby’s experience and expertise as we enter the next critical phase of our growth.”
Mr. Schilke is joining Achaogen after 13 years at Roche/Genentech where he has been, most recently, the CFO and Company Director of Roche Products Limited in the United Kingdom. In this role, Mr. Schilke was responsible for financial planning and analysis (FP&A), accounting, legal & financial compliance, supply chain, procurement and site services for Roche’s Pharma presence in the UK. Previously, Mr. Schilke had overall FP&A responsibility for Genentech's Commercial BioOncology business and, prior to Genentech, led a number of successful acquisition and spin-out deals as a member of the Roche Corporate M&A team.
Mr. Schilke received a Bachelor of Science degree in Chemical Engineering from Lafayette College in Easton, Pennsylvania, a Masters of Science degree from University of California in Berkeley, California, and a Masters of Business Administration degree from Cornell University’s Johnson Graduate School of Management in Ithaca, New York.
"With top-line results from the EPIC trial expected in Q1 2017, this is an exciting time to be joining Achaogen," said Mr. Schilke. "I am honored to be part of the Achaogen team and look forward to helping the company achieve its strategic objectives and financial goals as we work together to address the urgent need for new treatment options for serious MDR gram-negative infections."
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
“We are extremely pleased to have Toby joining the Achaogen team – he is a proven executive who has shaped and led successful teams,” said Kenneth Hillan, chief executive officer of Achaogen. “We look forward to leveraging Toby’s experience and expertise as we enter the next critical phase of our growth.”
Mr. Schilke is joining Achaogen after 13 years at Roche/Genentech where he has been, most recently, the CFO and Company Director of Roche Products Limited in the United Kingdom. In this role, Mr. Schilke was responsible for financial planning and analysis (FP&A), accounting, legal & financial compliance, supply chain, procurement and site services for Roche’s Pharma presence in the UK. Previously, Mr. Schilke had overall FP&A responsibility for Genentech's Commercial BioOncology business and, prior to Genentech, led a number of successful acquisition and spin-out deals as a member of the Roche Corporate M&A team.
Mr. Schilke received a Bachelor of Science degree in Chemical Engineering from Lafayette College in Easton, Pennsylvania, a Masters of Science degree from University of California in Berkeley, California, and a Masters of Business Administration degree from Cornell University’s Johnson Graduate School of Management in Ithaca, New York.
"With top-line results from the EPIC trial expected in Q1 2017, this is an exciting time to be joining Achaogen," said Mr. Schilke. "I am honored to be part of the Achaogen team and look forward to helping the company achieve its strategic objectives and financial goals as we work together to address the urgent need for new treatment options for serious MDR gram-negative infections."
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
